BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 18806565)

  • 1. C-11 choline PET/CT imaging for differentiating malignant from benign prostate lesions.
    Li X; Liu Q; Wang M; Jin X; Liu Q; Yao S; Liu S; Li J
    Clin Nucl Med; 2008 Oct; 33(10):671-6. PubMed ID: 18806565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer.
    Tuncel M; Souvatzoglou M; Herrmann K; Stollfuss J; Schuster T; Weirich G; Wester HJ; Schwaiger M; Krause BJ
    Nucl Med Biol; 2008 Aug; 35(6):689-95. PubMed ID: 18678354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis.
    Farsad M; Schiavina R; Castellucci P; Nanni C; Corti B; Martorana G; Canini R; Grigioni W; Boschi S; Marengo M; Pettinato C; Salizzoni E; Monetti N; Franchi R; Fanti S
    J Nucl Med; 2005 Oct; 46(10):1642-9. PubMed ID: 16204714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
    Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
    J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
    Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I
    J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas.
    Imani F; Agopian VG; Auerbach MS; Walter MA; Imani F; Benz MR; Dumont RA; Lai CK; Czernin JG; Yeh MW
    J Nucl Med; 2009 Apr; 50(4):513-9. PubMed ID: 19289420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
    Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B
    J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative detection of prostate cancer: a comparison with 11C-choline PET, 18F-fluorodeoxyglucose PET and MR imaging.
    Watanabe H; Kanematsu M; Kondo H; Kako N; Yamamoto N; Yamada T; Goshima S; Hoshi H; Bae KT
    J Magn Reson Imaging; 2010 May; 31(5):1151-6. PubMed ID: 20432351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases.
    Budiharto T; Joniau S; Lerut E; Van den Bergh L; Mottaghy F; Deroose CM; Oyen R; Ameye F; Bogaerts K; Haustermans K; Van Poppel H
    Eur Urol; 2011 Jul; 60(1):125-30. PubMed ID: 21292388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP).
    Panebianco V; Sciarra A; Lisi D; Galati F; Buonocore V; Catalano C; Gentile V; Laghi A; Passariello R
    Eur J Radiol; 2012 Apr; 81(4):700-8. PubMed ID: 21330082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of 11C-choline positron emission tomography-computed tomography and videomediastinoscopy in the evaluation of diseases of middle mediastinum.
    Liu Q; Peng ZM; Liu QW; Yao SZ; Zhang L; Meng L; Chen JH
    Chin Med J (Engl); 2006 Apr; 119(8):634-9. PubMed ID: 16635407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy.
    Martorana G; Schiavina R; Corti B; Farsad M; Salizzoni E; Brunocilla E; Bertaccini A; Manferrari F; Castellucci P; Fanti S; Canini R; Grigioni WF; D'Errico Grigioni A
    J Urol; 2006 Sep; 176(3):954-60; discussion 960. PubMed ID: 16890665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of a breath-holding acquisition method in PET/CT for pulmonary lesions.
    Yamaguchi T; Ueda O; Hara H; Sakai H; Kida T; Suzuki K; Adachi S; Ishii K
    Ann Nucl Med; 2009 Jan; 23(1):65-71. PubMed ID: 19205840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT.
    Testa C; Schiavina R; Lodi R; Salizzoni E; Corti B; Farsad M; Kurhanewicz J; Manferrari F; Brunocilla E; Tonon C; Monetti N; Castellucci P; Fanti S; Coe M; Grigioni WF; Martorana G; Canini R; Barbiroli B
    Radiology; 2007 Sep; 244(3):797-806. PubMed ID: 17652190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-fluoride PET/CT for bone scanning. Role of attenuation correction.
    Nagarajah J; Dannat T; Hartung V; Bockisch A; Rosenbaum-Krumme S
    Nuklearmedizin; 2012; 51(3):84-7. PubMed ID: 22366817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging prostate cancer with 11C-choline PET/CT.
    Reske SN; Blumstein NM; Neumaier B; Gottfried HW; Finsterbusch F; Kocot D; Möller P; Glatting G; Perner S
    J Nucl Med; 2006 Aug; 47(8):1249-54. PubMed ID: 16883001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver lesion detection and characterization in patients with colorectal cancer: a comparison of low radiation dose non-enhanced PET/CT, contrast-enhanced PET/CT, and liver MRI.
    Cantwell CP; Setty BN; Holalkere N; Sahani DV; Fischman AJ; Blake MA
    J Comput Assist Tomogr; 2008; 32(5):738-44. PubMed ID: 18830103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there an additional value of ¹¹C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules?
    Van den Bergh L; Koole M; Isebaert S; Joniau S; Deroose CM; Oyen R; Lerut E; Budiharto T; Mottaghy F; Bormans G; Van Poppel H; Haustermans K
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1486-92. PubMed ID: 22284686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer.
    Scher B; Seitz M; Albinger W; Tiling R; Scherr M; Becker HC; Souvatzogluou M; Gildehaus FJ; Wester HJ; Dresel S
    Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):45-53. PubMed ID: 16932935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data.
    Martinez-Möller A; Souvatzoglou M; Delso G; Bundschuh RA; Chefd'hotel C; Ziegler SI; Navab N; Schwaiger M; Nekolla SG
    J Nucl Med; 2009 Apr; 50(4):520-6. PubMed ID: 19289430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.